Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Short-term effect of humidified high nasal flow oxygen in critically ill patients

  • 958 Accesses

Introduction

Recently, humidified high-flow nasal cannula oxygen (HFNC) has gained popularity in treating patients with acute respiratory insufficiency. Studies have shown that HFNC generates a low level of positive airway pressure, reduction of airway resistance and flushes nasopharyngeal dead space leading to less work of breathing. However, in which type of patient HFNC could be of benefit, the short-term as well as long-term effects, tolerance and outcome are unknown. We used HFNC in a variety of patients. We evaluated the short-term effect of HFNC.

Methods

We retrospectively studied respiratory, oxygen-derived and hemodynamic parameters before and 1 hour after start of HFNC in 50 patients during the past 12 months. All patients were treated in a mixed medical, surgical, neurological ICU of a teaching hospital. The HFNC used consisted of an air-oxygen blender with adjustable FiO2 (0.21 to 1.0), delivering a modifiable gas flow up to 60 l/minute (Optiflow; Fisher & Paykel, Auckland, New Zealand).

Results

Fifty patients were included, 29 men and 21 women, mean age 65 ± 14, mean APACHE II score on admission 19 ± 5.9. The mean duration of HFNC was 22 ± 21 hours. Indications for HFNC could be divided into five categories: (1) no acceptance of noninvasive positive pressure ventilation (NPPV) (n = 8), (2) weaning from NPPV, (3) hypoxia (n = 14), (4) respiratory distress/discomfort (n = 9), and (5) other (n = 5). Despite the use of HFNC, in 15 patients intubation was unavoidable; group 1, n = 8, group 3, n = 6, group 4, n = 1. Oxygen saturation increased from 91 ± 7.2 to 97.5 ± 1.7 (P ≤0.05). PaO2/FiO2 ratio increased from 140 ± 79.1 to 169.8 ± 68 (P ≤0.05). PCO2 decreased from 6.5 ± 3.0 to 6.2 ± 2.9 mmHg (P ≤0.05). No significant differences were seen in heart rate, blood pressure and respiratory rate. Ten patients died, in eight patients of which the policy was not to reanimate and not to be intubated due to extensive comorbidity. Two patients died during treatment in the ICU due to underlying disease.

Conclusion

We used HFNC therapy for a variety of indications. In 70% of our study population HFNC was successful. Oxygen-derived parameters significantly increased after 1 hour of HFNC. HFNC was successful and well tolerated in patients weaning from NPPV. After noncompliance of NPPV in 42% of patients in our population, intubation could be avoided with the use of HFNC.

Author information

Correspondence to F Van Beers.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Van Beers, F., Van Hees, A., Van Rosmalen, J. et al. Short-term effect of humidified high nasal flow oxygen in critically ill patients. Crit Care 16, P137 (2012). https://doi.org/10.1186/cc10744

Download citation

Keywords

  • Noninvasive Positive Pressure Ventilation
  • Nasal Flow
  • Acute Respiratory Insufficiency
  • Extensive Comorbidity
  • Patient Intubation